Evidence map›Paper›PMID 42429417›Full record

ArticleMicrobiology spectrum2026

Synergism in drug combination of new tuberculosis antibiotics for drug-resistant

Run Huang, Yifan He, Jinghui Yang, Yidian Liu, Qin Sun, Ruoyan Ying, Wei Sha

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Run HuangDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.ORCID 0000-0003-3360-2297
Yifan HeDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.ORCID 0009-0006-5756-0166
Jinghui YangDepartment of Clinical Laboratory, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Yidian LiuDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.
Qin SunDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.ORCID 0000-0003-3445-920X
Ruoyan YingDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.ORCID 0009-0006-0825-973X
Wei ShaDepartment of Tuberculosis, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, People's Republic of China.ORCID 0000-0002-2099-8205

Funding

National Key Research and Development Program of China 2023YFC2307301
6 · The paper itself

Abstract

The treatment of drug-resistant tuberculosis (DR-TB) faces significant challenges. Novel antituberculosis drugs such as bedaquiline (BDQ), pretomanid (Pa824), and delamanid (DLM) offer a promising treatment for DR-TB. However, the synergistic effects of these drugs have been insufficiently explored. In this research, we evaluated the synergistic effects of two dual-drug combinations (BDQ-Pa824 and BDQ-DLM) and four triple-drug combinations (BDQ-DLM-clofazimine [CFZ], BDQ-DLM-linezolid [LZD], BDQ-Pa824-CFZ, and BDQ-Pa824-LZD) against 30

Indexed as

Antitubercular AgentsMycobacterium tuberculosisTuberculosis, Multidrug-ResistantDiarylquinolinesDrug CombinationsDrug SynergismDrug Therapy, CombinationHumansMicrobial Sensitivity TestsNitroimidazolesAntitubercular AgentsbedaquilineDiarylquinolinesDrug CombinationsNitroimidazolespretomanidcombined drug sensitivityDR-TBFICIMICtuberculosis

Identifiers

PMID42429417
PMCPMC13436375

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.